These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25636753)

  • 1. Discussion and challenges in the use and interpretation of utility assessment.
    Bremner KE
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):258-60. PubMed ID: 25636753
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?
    Snyder CF; Frick KD; Blackford AL; Herbert RJ; Neville BA; Carducci MA; Earle CC
    Cancer; 2010 Dec; 116(23):5391-9. PubMed ID: 20734396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: a high value target for cost containment.
    Gomella LG
    Can J Urol; 2013 Oct; 20(5):6888. PubMed ID: 24128823
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic burden of illness associated with localized prostate cancer in the United States.
    Gustavsen G; Gullet L; Cole D; Lewine N; Bishoff JT
    Future Oncol; 2020 Jan; 16(1):4265-4277. PubMed ID: 31802704
    [No Abstract]   [Full Text] [Related]  

  • 6. Podcasts made simple.
    Dasgupta P; Bultitude M
    BJU Int; 2013 Mar; 111(3):365. PubMed ID: 23444924
    [No Abstract]   [Full Text] [Related]  

  • 7. Valuing interventions for localised prostate cancer.
    Pickard R; Vale L
    BJU Int; 2013 Mar; 111(3):366-7. PubMed ID: 23444925
    [No Abstract]   [Full Text] [Related]  

  • 8. Adenocarcinoma of the prostate: an expensive way to die.
    Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
    Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
    Muralidhar V; Nguyen PL
    Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial treatment costs of organ-confined prostate cancer: a general perspective.
    Kommu SS; Eden CG; Luscombe CJ; Golash A; Persad RA
    BJU Int; 2011 Jan; 107(1):1-3. PubMed ID: 21176067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prostate cancer treatment bazaar: comment on "Physician visits prior to treatment for clinically localized prostate cancer".
    Barry MJ
    Arch Intern Med; 2010 Mar; 170(5):450-2. PubMed ID: 20212181
    [No Abstract]   [Full Text] [Related]  

  • 12. Testing the Assessment of New Radiation Oncology Technology and Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques.
    Duchesne GM; Haworth A; Bone E; Carter H; Ebert MA; Gagliardi F; Gibbs A; Hornby C; Martin A; Sidhom M; Wood M; Jackson M
    J Med Imaging Radiat Oncol; 2016 Feb; 60(1):129-37. PubMed ID: 26439588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
    Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
    Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
    Eldefrawy A; Katkoori D; Abramowitz M; Soloway MS; Manoharan M
    Urol Oncol; 2013 Jul; 31(5):576-80. PubMed ID: 21616691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
    Reinhold T; Dornquast C; Börgermann C; Weißbach L
    Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
    Schroeck FR; Jacobs BL; Bhayani SB; Nguyen PL; Penson D; Hu J
    Eur Urol; 2017 Nov; 72(5):712-735. PubMed ID: 28366513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Valorisation of brachytherapy and medico-economic considerations].
    Pommier P; Morelle M; Millet-Lagarde F; Peiffert D; Gomez F; Perrier L
    Cancer Radiother; 2013 Apr; 17(2):178-81. PubMed ID: 23601252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of out-of-pocket and indirect costs of prostate cancer.
    Jayadevappa R; Schwartz JS; Chhatre S; Gallo JJ; Wein AJ; Malkowicz SB
    Prostate; 2010 Aug; 70(11):1255-64. PubMed ID: 20658653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and economic considerations in the management of prostate cancer.
    Turini M; Redaelli A; Gramegna P; Radice D
    Pharmacoeconomics; 2003; 21(8):527-41. PubMed ID: 12751912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
    Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
    BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.